| |
 |
ARTICLES 
|
|
| Shifting the cancer paradigm: must we kill to cure? |
| H Schipper, CR Goh, and TL Wang |
|
JCO Apr 1 1995: 801–807.
[PDF]
|
 |
| p53: from molecular mechanisms to prognosis in cancer |
| CY Fung and DE Fisher |
|
JCO Apr 1 1995: 808–811.
[PDF]
|
|
|
Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases |
| |
C Preudhomme, I Dervite, E Wattel, M Vanrumbeke, M Flactif, JL Lai, B Hecquet, MC Coppin, B Nelken, and B Gosselin |
| |
JCO Apr 1 1995: 812–820.
[Abstract]
[PDF]
|
|
|
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis |
| |
PP Rosen, ML Lesser, CD Arroyo, M Cranor, P Borgen, and L Norton |
| |
JCO Apr 1 1995: 821–830.
[Abstract]
[PDF]
|
|
|
Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study |
| |
GT Budd, S Green, RM O'Bryan, S Martino, MD Abeloff, JJ Rinehart, R Hahn, J Harris, D Tormey, and J O'Sullivan |
| |
JCO Apr 1 1995: 831–839.
[Abstract]
[PDF]
|
|
|
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer |
| |
F Patrone, A Ballestrero, F Ferrando, F Brema, L Moraglio, M Valbonesi, P Basta, R Ghio, M Gobbi, and M Sessarego |
| |
JCO Apr 1 1995: 840–846.
[Abstract]
[PDF]
|
|
|
Breast irradiation postlumpectomy: development and evaluation of a decision instrument |
| |
TJ Whelan, MN Levine, A Gafni, H Lukka, EA Mohide, M Patel, and DL Streiner |
| |
JCO Apr 1 1995: 847–853.
[Abstract]
[PDF]
|
|
|
Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer |
| |
CC Mamby, RR Love, and KE Lee |
| |
JCO Apr 1 1995: 854–857.
[Abstract]
[PDF]
|
|
|
Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer |
| |
RP McQuellon, HB Muss, SL Hoffman, G Russell, B Craven, and SB Yellen |
| |
JCO Apr 1 1995: 858–868.
[Abstract]
[PDF]
|
|
|
Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group |
| |
K Furuse, K Kubota, M Kawahara, N Kodama, M Ogawara, M Akira, S Nakajima, M Takada, Y Kusunoki, and S Negoro |
| |
JCO Apr 1 1995: 869–875.
[Abstract]
[PDF]
|
|
|
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease |
| |
EE Vokes, M Kies, DJ Haraf, R Mick, WJ Moran, M Kozloff, B Mittal, H Pelzer, B Wenig, and W Panje |
| |
JCO Apr 1 1995: 876–883.
[Abstract]
[PDF]
|
|
|
Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma |
| |
B De Bernardi, M Conte, A Mancini, A Donfrancesco, P Alvisi, P Toma, F Casale, L Cordero di Montezemolo, PE Cornelli, and M Carli |
| |
JCO Apr 1 1995: 884–893.
[Abstract]
[PDF]
|
|
|
Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation |
| |
JG Villablanca, AA Khan, VI Avramis, RC Seeger, KK Matthay, NK Ramsay, and CP Reynolds |
| |
JCO Apr 1 1995: 894–901.
[Abstract]
[PDF]
|
|
|
Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societe Francaise d'Oncologie Pediatrique |
| |
F Doz, S Neuenschwander, D Plantaz, B Courbon, JC Gentet, E Bouffet, V Mosseri, JP Vannier, F Mechinaud, and L Desjardins |
| |
JCO Apr 1 1995: 902–909.
[Abstract]
[PDF]
|
|
|
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma |
| |
NM Bleehen, ES Newlands, SM Lee, N Thatcher, P Selby, AH Calvert, GJ Rustin, M Brampton, and MF Stevens |
| |
JCO Apr 1 1995: 910–913.
[Abstract]
[PDF]
|
|
|
Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma |
| |
M Harrison, D Tomlinson, and S Stewart |
| |
JCO Apr 1 1995: 914–920.
[Abstract]
[PDF]
|
|
|
Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu- A Study Group |
| |
|
| |
JCO Apr 1 1995: 921–928.
[Abstract]
[PDF]
|
|
|
Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases |
| |
N O'Rourke, E McCloskey, F Houghton, H Huss, and JA Kanis |
| |
JCO Apr 1 1995: 929–934.
[Abstract]
[PDF]
|
|
|
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma |
| |
S Cortelazzo, P Viero, P Bellavita, A Rossi, M Buelli, GM Borleri, S Marziali, R Bassan, B Comotti, and A Rambaldi |
| |
JCO Apr 1 1995: 935–941.
[Abstract]
[PDF]
|
|
|
Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake |
| |
E Even-Sapir, R Bar-Shalom, O Israel, A Frenkel, G Iosilevsky, N Haim, R Epelbaum, D Gaitini, GM Kolodny, and D Front |
| |
JCO Apr 1 1995: 942–946.
[Abstract]
[PDF]
|
|
|
Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial |
| |
PM Mauch, GP Canellos, LN Shulman, B Silver, NJ Tarbell, S Come, MS Rabin, and CN Coleman |
| |
JCO Apr 1 1995: 947–952.
[Abstract]
[PDF]
|
|
|
CEOP-B alternated with VIMB in intermediate-grade and high-grade non- Hodgkin's lymphoma: a pilot study |
| |
M De Lena, P Ditonno, V Lorusso, M Brandi, A Timurian, F Marzullo, V Ventrella, and A Pellecchia |
| |
JCO Apr 1 1995: 953–960.
[Abstract]
[PDF]
|
|
|
Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center |
| |
V Leblond, L Sutton, R Dorent, F Davi, MO Bitker, J Gabarre, F Charlotte, JJ Ghoussoub, C Fourcade, and A Fischer |
| |
JCO Apr 1 1995: 961–968.
[Abstract]
[PDF]
|
|
|
Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991 |
| |
CL Bennett, JL Armitage, GO Armitage, JM Vose, PJ Bierman, JO Armitage, and JR Anderson |
| |
JCO Apr 1 1995: 969–973.
[Abstract]
[PDF]
|
|
|
Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study |
| |
M Grever, K Kopecky, MK Foucar, D Head, JM Bennett, RE Hutchison, WE Corbett, PA Cassileth, T Habermann, and H Golomb |
| |
JCO Apr 1 1995: 974–982.
[Abstract]
[PDF]
|
|
|
Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia |
| |
MS Tallman, D Hakimian, C Zanzig, DK Hogan, A Rademaker, E Rose, and D Variakojis |
| |
JCO Apr 1 1995: 983–988.
[Abstract]
[PDF]
|
|
|
Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia |
| |
G Juliusson, D Heldal, E Hippe, M Hedenus, C Malm, K Wallman, CM Stolt, SA Evensen, F Albertioni, and G Tjonnfjord |
| |
JCO Apr 1 1995: 989–995.
[Abstract]
[PDF]
|
|
|
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin |
| |
PS Gill, BM Espina, F Muggia, S Cabriales, A Tulpule, JA Esplin, HA Liebman, E Forssen, ME Ross, and AM Levine |
| |
JCO Apr 1 1995: 996–1003.
[Abstract]
[PDF]
|
|
|
Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid- naive cancer patients with pain |
| |
F De Conno, C Ripamonti, L Saita, T MacEachern, J Hanson, and E Bruera |
| |
JCO Apr 1 1995: 1004–1008.
[Abstract]
[PDF]
|
|
|
Implications of the p53 tumor-suppressor gene in clinical oncology |
| |
F Chang, S Syrjanen, and K Syrjanen |
| |
JCO Apr 1 1995: 1009–1022.
[Abstract]
[PDF]
|
|
|
Clinical applications of hematopoietic growth factors |
| |
JM Vose and JO Armitage |
| |
JCO Apr 1 1995: 1023–1035.
[Abstract]
[PDF]
|
|
|
Review of the preclinical pharmacology and comparative efficacy of 5- hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis |
| |
EA Perez |
| |
JCO Apr 1 1995: 1036–1043.
[Abstract]
[PDF]
|
|
| Regarding the dilemma of adjuvant therapy in postmenopausal patients with node-positive, estrogen receptor-positive breast cancer: are we better informed? |
| JA Roy, D de Valeriola, and M Piccart |
|
JCO Apr 1 1995: 1044–1045.
[PDF]
|
|
| Do glucocorticoids influence the survival of myeloma patients? |
| DE Bergsagel |
|
JCO Apr 1 1995: 1045–1047.
[PDF]
|
|
